News & Updates

12 March, 2023
U.S. Department of Defense Awards Rafa Laboratories Production follow-on Agreement of over $45 million
Rafa recently secured a 45 million $US deal with the US Department of Defense for its midazolam autoinjector which was approved by the US-FDA in 2022. Rafa is very proud of this achievement and hopes to bring this life saving product to people in need all over the world. We would like to thank the...
Read more
05 September, 2022
Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector. The first in market product was developed in cooperation with the U.S. Department of Defense
Jerusalem, August, 2022 - Rafa Laboratories LTD. (" Rafa ") is pleased to announce the U.S. Food and Drug Administration has approved its "first in market" 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The development of the product is yet another fruitful...
Read more
03 August, 2022
Rafa Laboratories to acquire a significant stake in ExCEEd Orphan and expand its international capabilities in medicines addressing rare diseases
Jerusalem, Israel and Prague, Czech Republic, August 1 st , 2022. Rafa Laboratories LTD. (" Rafa ") and ExCEEd Orphan s.r.o (" ExCEEd ") announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe (“ CEE ”) and Israel. Under the agreement, and as...
Read more